[{"orgOrder":0,"company":"Inotrem","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"FRANCE","productType":"Peptide, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Nangibotide","moa":"Triggering receptor expressed on myeloid cells 1","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Inotrem","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Inotrem \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Inotrem \/ Undisclosed"},{"orgOrder":0,"company":"Inotrem","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"FRANCE","productType":"Peptide, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Nangibotide","moa":"Triggering receptor expressed on myeloid cells 1","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Inotrem","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Inotrem \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Inotrem \/ Undisclosed"},{"orgOrder":0,"company":"Inotrem","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"FRANCE","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Nangibotide","moa":"Triggering receptor expressed on myeloid cells 1","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Inotrem","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Inotrem \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Inotrem \/ Undisclosed"},{"orgOrder":0,"company":"Inotrem","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"FRANCE","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Nangibotide","moa":"Triggering receptor expressed on myeloid cells 1","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Inotrem","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Inotrem \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Inotrem \/ Undisclosed"},{"orgOrder":0,"company":"Inotrem","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"FRANCE","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Nangibotide","moa":"Triggering receptor expressed on myeloid cells 1","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Inotrem","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Inotrem \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Inotrem \/ Undisclosed"},{"orgOrder":0,"company":"Inotrem","sponsor":"Roche Diagnostics GmbH","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"FRANCE","productType":"Peptide, Unconjugated","year":"2020","type":"Licensing Agreement","leadProduct":"Nangibotide","moa":"Triggering receptor expressed on myeloid cells 1","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Inotrem","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Inotrem \/ Roche Diagnostics GmbH","highestDevelopmentStatusID":"8","companyTruncated":"Inotrem \/ Roche Diagnostics GmbH"}]